Business, energy, technology, markets and global industry news from Business News Today

China National Medical Products Administration

PharmaDeviceNews China National Medical Products Administration
Representative image of pharmaceutical manufacturing and respiratory medicine research. Lupin Limited’s China approval for oseltamivir phosphate oral suspension highlights the continuing role of paediatric-friendly antiviral formulations in influenza treatment access.
Pharma & Biotech

Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?

Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.

Read More
Representative image: A modern oncology research lab reviewing thoracic scan data, illustrating the clinical push behind Wenda Pharma’s NHWD-870 breakthrough therapy designation for advanced NUT carcinoma in China.
Medical Devices & Diagnostics

Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma

NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.

Read More
Pharma & Biotech

Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race

DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.

Read More
Representative image of a dermatology consultation and treatment planning, used to illustrate Lynk Pharmaceuticals’ zemprocitinib New Drug Application acceptance in China for moderate-to-severe atopic dermatitis.
Pharma & Biotech

Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?

Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.

Read More
Pharma & Biotech

Can Ascletis’ denifanstat reshape acne treatment by targeting fatty acid synthesis?

Ascletis' acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.

Read More